Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing: 1–36
Headlines: 40
Sources here: 15
Companies here: 11

Current section France Biotechnology news Latest headline 16:08, 14 August 2026

Latest16:08 · 14 August 2026

finance.yahoo.com Analyst action

European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading

European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.35% to 1,962.14 on the S&P Europe Select ADR Index, which is up 0.17% for the week so far.From continental Europe, the gainers were led by semiconductor company Silver Upgrade to read this MT Newswires article and get so much more. …

Provider-linked mention 🇫🇷 France

Read at finance.yahoo.com

Sharemaestro market context Price below Trend Line 52 weeks -5.1% · Next-week setup negative 39.3%

Just inNext headlines

06:00 14 Aug 2026

finance.yahoo.com Earnings Main company 🇫🇷 France

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …

VLA main company

Sharemaestro market context New activity signal 52 weeks -52.6%

16:14 13 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇫🇷 France

European Equities Traded in the US Rise in Thursday Trading

European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade …

ALCLS mentioned

Sharemaestro market context Price below Trend Line 52 weeks -5.1% · Next-week setup negative 39.3%

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

10:01 13 Aug 2026

Zonebourse Market update Main company 🇫🇷 France

Valneva dévoile des résultats en baisse comme prévu

VLA main company

Sharemaestro market context New activity signal 52 weeks -52.6%

07:05 13 Aug 2026

seekingalpha.com Earnings Main company 🇫🇷 France

Valneva GAAP EPS of -€0.35, revenue of €65.84M; reaffirms FY 2026

* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (-32.5% Y/Y). * Solid cash position of €121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on …

VLA main company

Sharemaestro market context New activity signal 52 weeks -52.6%

06:00 13 Aug 2026

finance.yahoo.com Earnings Main company 🇫🇷 France

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …

VLA main company

Sharemaestro market context New activity signal 52 weeks -52.6%

11:21 10 Aug 2026

nasdaq.com Deals and strategy Main company 🇫🇷 France

Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO

(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in …

IPH main company

Sharemaestro market context Trend signal active 52 weeks -23.2% · Next-week setup negative 44.5%

08:10 10 Aug 2026

nasdaq.com Deals and strategy Main company 🇫🇷 France

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in …

IPH main company

Sharemaestro market context Trend signal active 52 weeks -23.2% · Next-week setup negative 44.5%

07:36 10 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇫🇷 France

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study …

IPH main company

Sharemaestro market context Trend signal active 52 weeks -23.2% · Next-week setup negative 44.5%

11:30 7 Aug 2026

Market source Market update Main company 🇫🇷 France